CCR2-targeting pepducins reduce T cell-nociceptor interaction driving bone cancer pain
Élora Midavaine, Rebecca L. Brouillette, Élizabeth Théberge, Christine E. Mona, Sakeen W. Kashem, Jérôme Côté, Vera Zeugin, Élie Besserer‐Offroy, Jean‐Michel Longpré, Éric Marsault, Philippe Sarret
The paper shows that CCR2-targeting pepducin PP101 reduces bone cancer pain by inhibiting T cell infiltration and neuroimmune communication in dorsal root ganglia without adverse effects.
bioRxiv · Sep 15, 2023 · PreprintNeuroscience